Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer
Ie-Wen Sim, Kerrie M Sanders, Gelsomina L Borromeo, John F Seymour, Peter R Ebeling
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | ENDOCRINE SOC | Published : 2015
CONTEXT: Medication-related osteonecrosis of the jaw (MRONJ) is an infrequent, but severely debilitating condition. Given the significant morbidity attributable to MRONJ and the challenges associated with its management, prevention is crucial. OBJECTIVE: We sought to evaluate the effectiveness of an active dental intervention in reducing MRONJ incidence. DESIGN AND SETTING: We identified all patients who received antiresorptive drug therapy at a specialized cancer center between January 2003 and December 2013 through hospital pharmacy records, whereas confirmed cases of MRONJ were identified through a hospital database. MAIN OUTCOME MEASURES: The incidence of MRONJ before and after the imple..View full abstract
I.-W.S., G.L.B., and J.F.S. have nothing to disclose. K.M.S. receives research funding from Merck. P.R.E. receives research funding from Merck, Novartis, Eli-Lilly and Amgen.